Orexigen Shares Up 23% On News That Takeda Pharma Agreed to Commercialize Contrave

Loading...

Sign in or sign up now!
Alert icon
Upgrade to the latest Flash Player for improved playback performance. Upgrade now or more info.
250 views
Loading...
Alert icon
Sign in or sign up now!
Alert icon

Uploaded by on Sep 2, 2010

Orexigen Therapeutics (NASDAQ:OREX) shares are trading 23.10% higher at $5.65 on news that Takeda Pharmaceutical has agreed to commercialize Orexigen's new diet drug Contrave in North America, subject to regulatory approval.

The company expects to receive a decision from the FDA by January 31, 2011.

SmarTrend is bullish on shares of Orexigen Therapeutics and our subscribers were alerted to buy on July 14, 2010 at $5.26. The stock has risen 6.7% since the alert was issued.

  • likes, 1 dislikes

Link to this comment:

Share to:
see all

All Comments (0)

Sign In or Sign Up now to post a comment!
Loading...

Alert icon
0 / 00Unsaved Playlist Return to active list
    1. Your queue is empty. Add videos to your queue using this button:
      or sign in to load a different list.
    Loading...Loading...Saving...
    • Clear all videos from this list
    • Learn more